• Users Online: 224
  • Print this page
  • Email this page


 
 Table of Contents  
CASE REPORT
Year : 2018  |  Volume : 8  |  Issue : 3  |  Page : 173-175

Bilateral anterior uveitis after immunotherapy for malignant melanoma


1 Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan
2 Department of Ophthalmology, Taipei Veterans General Hospital; Department of Ophthalmology, School of Medicine, National Yang-Ming University, Taipei, Taiwan

Date of Submission17-Sep-2017
Date of Acceptance01-May-2018
Date of Web Publication20-Sep-2018

Correspondence Address:
Dr. De-Kuang Hwang
Department of Ophthalmology, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei 11217
Taiwan
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/tjo.tjo_88_17

Rights and Permissions
  Abstract 


Immune checkpoint blockade therapy is relatively a new treatment for cancer which has shown promising results. However, immune-related side effects including uveitis have occasionally been reported during this therapy. Herein, we report the case of a 65-year-old male who suffered bilateral anterior uveitis after immune checkpoint blockade therapy with pembrolizumab and ipilimumab for malignant melanoma. His symptoms and signs improved after topical treatment with corticosteroids. Clinicians should be aware that uveitis can be an immune-related adverse event of immunotherapy.

Keywords: Immune checkpoint blockade, ipilimumab, pembrolizumab, uveitis


How to cite this article:
Chang CJ, Chen SJ, Hwang DK, Liu CJ. Bilateral anterior uveitis after immunotherapy for malignant melanoma. Taiwan J Ophthalmol 2018;8:173-5

How to cite this URL:
Chang CJ, Chen SJ, Hwang DK, Liu CJ. Bilateral anterior uveitis after immunotherapy for malignant melanoma. Taiwan J Ophthalmol [serial online] 2018 [cited 2019 Jan 20];8:173-5. Available from: http://www.e-tjo.org/text.asp?2018/8/3/173/233472




  Introduction Top


Uveitis is a sight-threatening disease which is defined as intraocular inflammation involving the iris, ciliary body, or choroid. More than 30 etiologies have been reported to cause uveitis,[1] and treatment and outcomes are mainly associated with its etiology and clinical course. Although uncommon, various local and systemic medications including antimicrobial drugs, bisphosphonates, vaccines, and antiglaucomatous drugs can cause uveitis.[2]

Immune checkpoint blockade therapy was developed and approved by the Food and Drug Administration in the United States to treat cancer in 2011. It enhances human autoimmune reactions against cancer cells by blocking checkpoint signals, which are the inhibitory signals of T-cell-mediated adaptive immunity.[3],[4] However, inhibition of these pathways may result in persistent T-cell activation, increased cytokine production, and enhanced T-cell-mediated immune responses.[5],[6] Various immune-related adverse events have been reported, including those affecting the skin, gastrointestinal tract, kidneys, central nervous system, liver, pancreas, and endocrine system. The severity of these events ranges from minor symptoms to life-threatening complications.[7],[8],[9],[10] In addition, ocular side effects including dry eyes and noninfectious uveitis have also been reported.[7],[11],[12]

Herein, we present a patient with skin and brain melanoma who developed bilateral anterior uveitis accompanied with systemic signs after immunotherapy.


  Case Report Top


A 65-year-old male presented with acute blurring, redness, and discomfort in both eyes for 3 days. His visual acuity was 6/10 in the right eye and 6/8.6 in the left eye. The intraocular pressure was 7 mmHg in the right eye and 8 mmHg in the left eye. A slit-lamp examination showed bilateral anterior uveitis with congested conjunctiva, corneal edema, multiple whitish keratic precipitates, 2+ inflammatory cells, 1+ of flare, and focal iris posterior synechia in both eyes [Figure 1]a. Mild cataract was also observed. No vitreous cells, haze, or focal chorioretinal lesions were noted in either eye. Optical coherence tomography revealed normal macula contours and normal ellipsoid zones.
Figure 1: Acute anterior uveitis in a 65-year-old male after immunotherapy. (a) Corneal edema and multiple whitish keratic precipitates were noted. Anterior chamber cells and iris posterior synechia were also found by slit-lamp examination. (b) After treatment, all signs of uveitis including conjunctival congestion, edematous cornea, keratic precipitates, anterior chamber cells, and iris synechia subsided.

Click here to view


Tracing back the patient's history, he had been diagnosed with skin malignant melanoma and received surgical treatment in 2012. Unfortunately, brain and lung metastases were found 3 years after the diagnosis, and he had been receiving immune checkpoint blockade therapy with intravenous infusions of pembrolizumab (Keytruda; Merck) 100 mg in combination with ipilimumab (Yervoy; Bristol-Myers Squibb) 50 mg since then. This episode of blurred vision occurred 2 weeks after the third infusion of immunotherapy. At the presentation of uveitis, he reported a skin rash and an itching sensation. Systemic workup revealed mild anemia (hemoglobin: 9.9 g/dL), impaired renal function (serum creatinine level: 1.55 mg/dL), and a slightly elevated level of serum C-reactive protein (0.58 mg/dL). A chest radiograph showed lung metastasis without lymphadenopathy. Other blood tests including human leukocyte antigen B27 were all negative.

He was treated with a topical 1% prednisolone (Pred Forte; Allergan) every 2 h and topical 1% atropine sulfate (Antol) twice a day. In addition, 10 mg of oral prednisolone was prescribed for 3 days due to his skin reaction. After 1 month of treatment, his vision recovered to 6/6 in the right eye and 6/7.5 in the left eye. Moreover, all signs of uveitis including conjunctival congestion, edematous cornea, keratic precipitates, anterior chamber cells, and iris synechiae subsided [Figure 1]b.

He subsequently received a few more courses of pembrolizumab (Keytruda; Merck) monotherapy. No signs of progression or metastasis of his malignant melanoma were noted during the following 1 year, and there was no recurrence of any uveitis. However, poliosis and vitiligo developed and progressed during follow-up [Figure 2].
Figure 2: Poliosis and vitiligo were found in the patient after >1 year of immunotherapy

Click here to view



  Discussion Top


Immune checkpoint blockade therapy is a novel treatment for melanoma, nonsmall cell lung cancer, and renal cell carcinoma.[3],[13] An immune checkpoint pathway is a pathway that downregulates immune functions to maintain immune homeostasis. Two components are involved in this pathway: programmed cell death protein-1 (PD-1) and PD-1 ligand 1 (PDL-1) receptor–ligand pair, and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4).[3],[4],[14],[15] Cancer cells seem to induce immune checkpoint pathways to evade immune attack. Nivolumab and pembrolizumab are antibodies that block PD-1, and ipilimumab is used to block CTLA4. These antibodies are approved for human use as cancer treatment.

Several adverse effects of immune checkpoint blockade have been reported, including uveitis.[7],[8],[9] Robinson et al. reported two cases who received CTLA4 blockade therapy for metastatic melanoma and developed bilateral anterior uveitis and vitritis after treatment.[11] They were treated with topical steroids and CTLA4 blockade therapy was discontinued, after which their uveitis resolved; however, one of the patients was found to have progression of melanoma. Abdel-Wahab et al. performed a systematic review of adverse effects associated with immune checkpoint blockade and found that uveitis was reported in 10.3% of patients who received ipilimumab and in 10% of patients who received pembrolizumab although no ophthalmologic side effects were reported in patients who received nivolumab.[7] Once uveitis occurs, treatment includes discontinuation of the immunotherapy, topical steroids with 1% prednisolone, and an oral form in severe cases, and immunomodulatory agents such as drug-modifying antirheumatic drugs and infliximab can also be considered.[8]

Melanocytes, melanin, and pigment in the human uvea tissues and retina share many surface proteins with skin melanocytes. Since immune checkpoint blockade is typically used to treat patients with melanoma via enhancing immune reactions, it is possible that such therapy may trigger autoantibodies against normal melanocytes in uvea tissue, leading to uveitis. Both ipilimumab and pembrolizumab have been reported to cause immune-related side effects including uveitis.[7] Our patient suffered from acute onset of uveitis (<3 days) 2 weeks after the third infusion of a combination of these two medications. His uveitis resolved after topical steroid treatment and discontinuation of ipilimumab. He received a few more courses of pembrolizumab alone, and no uveitis was noted even without topical steroids. Hence, we suspect that ipilimumab caused uveitis in this patient. Although no uveitis was noted after subsequent courses of pembrolizumab therapy, the occurrence of poliosis and vitiligo supports autoimmune reactions to systemic normal melanocytes.


  Conclusion Top


Immune checkpoint blockade used to treat cancer patients may be a cause of uveitis. Although the severity of ocular side effects is usually minor, topical or systemic anti-inflammatory treatments including steroids, immunomodulatory agents, and biologic agents can be used to control these immune-related side effects. Drug discontinuation should be considered if the adverse events are too severe although subsequent recurrence or metastasis of the malignancy is possible.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

The authors declare that there are no conflicts of interests of this paper.



 
  References Top

1.
Barisani-Asenbauer T, Maca SM, Mejdoubi L, Emminger W, Machold K, Auer H, et al. Uveitis – A rare disease often associated with systemic diseases and infections – A systematic review of 2619 patients. Orphanet J Rare Dis 2012;7:57.  Back to cited text no. 1
    
2.
Shifera AS, Kopplin L, Lin P, Suhler EB. Drug-induced uveitis. Int Ophthalmol Clin 2015;55:47-65.  Back to cited text no. 2
    
3.
Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 2016;16:275-87.  Back to cited text no. 3
    
4.
Turnis ME, Andrews LP, Vignali DA. Inhibitory receptors as targets for cancer immunotherapy. Eur J Immunol 2015;45:1892-905.  Back to cited text no. 4
    
5.
Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006;18:206-13.  Back to cited text no. 5
    
6.
Tarhini A, Lo E, Minor DR. Releasing the brake on the immune system: Ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm 2010;25:601-13.  Back to cited text no. 6
    
7.
Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse events associated with immune checkpoint blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221.  Back to cited text no. 7
    
8.
Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 2015:76-83. doi: 10.14694/EdBook_AM.2015.35.76.  Back to cited text no. 8
    
9.
Kähler KC, Hassel JC, Heinzerling L, Loquai C, Mössner R, Ugurel S, et al. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. J Dtsch Dermatol Ges 2016;14:662-81.  Back to cited text no. 9
    
10.
Chen TW, Razak AR, Bedard PL, Siu LL, Hansen AR. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol 2015;26:1824-9.  Back to cited text no. 10
    
11.
Robinson MR, Chan CC, Yang JC, Rubin BI, Gracia GJ, Sen HN, et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: A new cause of uveitis. J Immunother 2004;27:478-9.  Back to cited text no. 11
    
12.
Abdel-Rahman O, Oweira H, Petrausch U, Helbling D, Schmidt J, Mannhart M, et al. Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: A systematic review. Expert Rev Anticancer Ther 2017;17:387-94.  Back to cited text no. 12
    
13.
Jackson CM, Lim M, Drake CG. Immunotherapy for brain cancer: Recent progress and future promise. Clin Cancer Res 2014;20:3651-9.  Back to cited text no. 13
    
14.
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.  Back to cited text no. 14
    
15.
Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annu Rev Med 2014;65:185-202.  Back to cited text no. 15
    


    Figures

  [Figure 1], [Figure 2]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Introduction
Case Report
Discussion
Conclusion
References
Article Figures

 Article Access Statistics
    Viewed516    
    Printed52    
    Emailed0    
    PDF Downloaded79    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]